WFH NETWORK

COVID-19 Treatment and Vaccination for PWBDs

 
Details

Year: 2021

Language: English

Author(s): World Federation of Hemophilia

Date: March 12, 2021

Also Available In: Russian, Arabic, French, Spanish

Access Webinar
Additional Information

Listen to this 90-minute webinar presented on March 12, 2021 to learn about the latest WFH guidance regarding COVID-19 treatment and vaccination for People with Bleeding Disorders (PWBDs). The objective of this webinar was to address questions related to COVID-19 in PWBD. It provided an opportunity for attendees to follow the latest WFH recommendations for prevention and treatment, get more information on COVID-19 vaccines, better understand the current state on access to vaccines globally and risks to PWBDs related to these vaccines.

The session was chaired by Glenn Pierce (WFH Vice President, Medical).

Miguel Escobar (WFH Medical Board Member), Cedric Hermans (WFH Medical Board Member), Johnny Mahlangu (Professor of Haematology), Radoslaw Kaczmarek (WFH Coagulation Product Safety, Supply, and Access Committee Chair) and Ioana Ghiga (Technical Officer, WHO) presented the epidemiology of COVID-19 for PWBD, treatment and vaccination guidance for PWBDs, shared perspectives on treatment from South Africa including different variants, and addressed the question of accessibility of vaccines globally through CEPI, GAVI, WHO and UNICEF COVAX Facility.

To download a pdf of the slides of the webinar, click the icon below.

pdf_icon

 

The WFH does not engage in the practice of medicine and under no circumstances recommends particular treatment for specific individuals. For diagnosis or consultation on a specific medical problem, the WFH recommends that you contact your physician or local treatment centre. Before administering any products, the WFH urges patients to check dosages with a physician or hemophilia centre staff, and to consult the pharmaceutical company’s printed instructions.

The WFH does not promote any particular pharmaceutical product and any mention of any commercial brand in this presentation is strictly for educational purposes.